TECTONIC THERAPEUTIC INC

TECXNASDAQ

🏆 #2296 by market capEarnings Nov 4US Equity

$31.87▼ $0.82 (−2.57%)

Market closed · at close

1h—

24h▼ 2.6%

7d▲ 8.3%

14d▲ 12.3%

30d▼ 7.2%

1y▲ 45.7%

🏦Market Cap

$601M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $31.36 – $32.50
52-Week Range: $14.39 – $39.53
Volume: $2.42B
Avg Volume: $2.80B
Shares Outstanding: 18.9M
Next Earnings: Oct 11, 2026

Fundamentals Snapshot

Annual Revenue: $54M
Last Q Revenue: $15M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.46
Dividend Yield: —

Why Investors Own TECX

✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
✓Healthy economics — 58% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$54M▲ +11.9% YoY

Gross Margin (TTM)

58.2%▲ +2.5% YoY

Operating Income (TTM)

$6M▲ +11.9% YoY

Free Cash Flow (TTM)

$11M▲ +11.9% YoY

About TECTONIC THERAPEUTIC INC

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

🦦